2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting systemAdverse cardiovascular events in patients treated with mogamulizumab
Kwan J, Henry M, Cook K, Higgins A, Cuomo J, Foss F, Baldassarre L. Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus Cardiology Research And Practice 2021, 9: 100049. PMID: 38559371, PMCID: PMC10978139, DOI: 10.1016/j.ahjo.2021.100049.Peer-Reviewed Original ResearchAdverse cardiovascular eventsMogamulizumab therapyCardiovascular eventsHeart failureAdverse outcomesNon-cardiovascular eventsWorld Health Organization databaseFatal adverse outcomesT-cell leukemiaACE occurrenceMogamulizumab treatmentNew hypertensionAdverse eventsCardiac deathVentricular arrhythmiasFatal outcomeUnique patientsCardiovascular toxicityMyocardial infarctionImportant treatmentHigh mortalityPatientsMogamulizumabTherapyOrganization database
2020
Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis
Arbune A, Soufer A, Baldassarre L. Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis. Current Cardiovascular Imaging Reports 2020, 13: 3. DOI: 10.1007/s12410-019-9521-5.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsEndomyocardial biopsyAdverse eventsCases of ICIImmune-related adverse eventsCardiac magnetic resonance imagingImmune adverse eventsDiagnosis of myocarditisBiventricular ejection fractionAdvanced MRI techniquesInvasive endomyocardial biopsyMagnetic resonance imagingPurpose of ReviewWithGold standard testAssociated myocarditisCheckpoint inhibitorsCMR findingsMyocardial inflammationEjection fractionSerial monitoringNoninvasive testsPrognostic informationTissue characterization informationCardiac biomarkersParametric mapping techniques